HK Stock Market Move | CATHAY PAC AIR (00293) soared over 3%, with mid-term net profit increasing by 71% year-on-year, and dividends raised to 26 Hong Kong cents.
Cathay Pacific Airways (00293) rose over 3% in the afternoon, and as of the time of writing, it is up 3.06%, trading at HKD 14.84, with a transaction volume of HKD 223 million.
CATHAY PAC AIR (00293) rose more than 3% in the afternoon, closing at a 3.06% increase, priced at HKD 14.84, with a transaction volume of HKD 223 million.
In terms of news, CATHAY PAC AIR released its mid-term results for 2026 at noon today, reporting a revenue of HKD 68.061 billion, a year-on-year increase of 25.3%; profit attributable to shareholders of Jiangxi Guotai Group reached HKD 6.243 billion, a year-on-year increase of 71%; earnings per share were HKD 0.995, and a proposed ordinary share dividend of HKD 0.26 per share was announced, marking a year-on-year increase of 30%. The announcement indicated that the performance benefited from the sustained robust core demand of CATHAY PAC AIR and Cathay Cargo, improved performance of Hong Kong Express, as well as better profit contributions from affiliated companies.
It is worth mentioning that the easing situation between the U.S. and Iran has led to a significant correction in oil prices. U.S. President Trump stated in an interview with Fox News on the 4th that the Strait of Hormuz will be "opened soon," otherwise Iran will face "severe strikes." Previously, U.S. Treasury Secretary Mnuchin mentioned that an agreement regarding the Strait of Hormuz could be reached on the 4th or 5th. Mnuchin stated, "Right now, we can also see a number of ships leaving the Strait of Hormuz."
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





